ITCC - Innovative Therapies for Children with Cancer in Europe

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

  • A Phase I/II Study of the Oral TRK Inhibitor LOXO 101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors

  • INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies

  • Pilot study of nivolumab in paediatric patients with hypermutant cancers

  • Ibrutinib randomized safety and efficacy study in pediatric patients with mature B-cell NHL, including Burkitt lymphoma/Leukemia and Diffuse Large B-cell Lymphoma

  • A phase I/II, multi-center, dose-escalating study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of Quizartinib administered in combination with re-induction chemotherapy,...

  • A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric Patients with Select Relapsed or Refractory Malignancies

  • An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age with Relapsed/Refractory Precursor B-cell...

  • Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with PD or as consolidative immunotherapy in...